Aileron Therapeutics Sets August 20th Shareholder Meeting

TL;DR

Aileron Therapeutics (ALRN) proxy filed: shareholder meeting Aug 20th to vote on directors & auditors.

AI Summary

Aileron Therapeutics, Inc. filed its definitive proxy statement (DEF 14A) on July 9, 2024, for its annual meeting of stockholders scheduled for August 20, 2024. The filing outlines the agenda for the meeting, which includes the election of directors and the ratification of the company's independent registered public accounting firm. No specific proposals or executive compensation details are detailed in this initial summary, but it sets the stage for shareholder decisions.

Why It Matters

This filing is crucial for shareholders as it details the agenda for the annual meeting, allowing them to understand and vote on key corporate matters, including director elections.

Risk Assessment

Risk Level: low — This is a routine proxy filing outlining an upcoming shareholder meeting and does not contain new financial risks or significant operational changes.

Key Players & Entities

• Aileron Therapeutics, Inc. (company) — Registrant
• August 20, 2024 (date) — Annual Meeting Date
• July 9, 2024 (date) — Filing Date

FAQ

Key Financial Figures

• $16,000 — tion of proxies for an aggregate fee of $16,000. In addition to solicitation by mail, o
• $700.0 m — ock held by non-affiliates is less than $700.0 million, and our annual revenue was less
• $100.0 million — n, and our annual revenue was less than $100.0 million during our most recently completed fisc
• $250.0 million — ock held by non-affiliates is less than $250.0 million or (ii) our annual revenue was less tha
• $700.0 million — ock held by non-affiliates is less than $700.0 million. As a smaller reporting company, we may

Filing Documents

• d854372ddef14a.htm (DEF 14A) — 358KB
• g854372g00j01.jpg (GRAPHIC) — 56KB
• g854372g00p02.jpg (GRAPHIC) — 53KB
• g854372g23z17.jpg (GRAPHIC) — 32KB
• g854372g32g32.jpg (GRAPHIC) — 283KB
• g854372g33g33.jpg (GRAPHIC) — 209KB
• 0001193125-24-176585.txt ( ) — 1230KB

From the Filing

DEF 14A 1 d854372ddef14a.htm DEF 14A DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the RegistrantFiled by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to 240.14a-12 AILERON THERAPEUTICS, INC. (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 2(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. Table of Contents AILERON THERAPEUTICS, INC. 12407 N. Mopac Expy. Suite 250 #390 Austin, Texas 78758 (737) 802-1989 NOTICE OF 2024 ANNUAL MEETING OF STOCKHOLDERS To Be Held on August 20, 2024 Dear Stockholders: You are cordially invited to attend the 2024 annual meeting of stockholders of Aileron Therapeutics, Inc. to be held on Tuesday, August 20, 2024 at 9:00 a.m., Eastern Daylight Time. We are very pleased that this years annual meeting will be a virtual meeting of stockholders, conducted solely online via live webcast. There is no physical location for the annual meeting. You will be able to attend and participate in the annual meeting online, vote your shares electronically and submit your questions prior to and during the meeting by visiting: www.meetnow.global/M55G7U9 . Further information about how to attend the annual meeting online, vote your shares during the meeting and submit questions during the meeting is included in the accompanying proxy statement. At the annual meeting, stockholders will consider and vote on the following matters: 1. The election of two Class I directors to serve for a term expiring at the 2027 annual meeting of stockholders and until his successor has been duly elected and qualified; 2. A non-binding, advisory vote to approve named executive officer compensation; 3. The ratification of the appointment of Marcum LLP as our independent registered public accounting firm for the 4. The transaction of any other business that may properly come before the annual meeting or any adjournment or postponement thereof. Stockholders of record at the close of business on June 26, 2024, will be entitled to notice of and to vote at the annual meeting or any adjournment or postponement thereof. We have elected to provide access to our proxy materials over the Internet under the Securities and Exchange Commissions notice and access rules. We believe that providing our proxy materials over the Internet expedites stockholders receipt of proxy materials, lowers costs, and reduces the environmental impact of our annual meeting. We encourage all stockholders to attend the annual meeting. Whether or not you expect to attend the annual meeting online, please vote your shares to ensure your representation and the presence of a quorum at the annual meeting. Your vote is important regardless of the number of shares you own. If your shares are held in street name, that is, held for your account by a broker or other nominee, you will receive instructions from the holder of record that you must follow for your shares to be voted. Please review the instructions on each of your voting options described in the proxy statement. A list of registered stockholders as of the close of business on June 26, 2024 will be available for examination by any stockholder for any purpose germane to the annual meeting for a period of 10 days prior to the annual meeting. If you wish to view this list, please contact our Corporate Secretary at Aileron Therapeutics, Inc., 12407 N. Mopac Expy. Suite 250 #390, Austin, Texas 78758, Attention: Corporate Secretary. Table of Contents Thank you for your ongoing support and continued interest in Aileron Therapeutics, Inc. By Order of the Board of Directors, /s/ Brian Windsor, Ph.D. Brian Windsor, Ph.D. President and Chief Executive Officer Austin, Texas July 9, 2024 Important Notice Regarding Internet Availability of Proxy Materials: The attached proxy statement and our 2023 Annual Report to Stockholders, which includes our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, are available at www.envisionreports.com/ALRN-AM . These documents are also available to any stockholder who wishes to receive a paper copy by calling 1-866-641-4276, or by emailing investorvote@computershare.com with Proxy Materials Aileron Therapeutics in the subject line, or by submitting a request over the Internet at www.envisionreports.com/ALRN-AM . Table of Contents TABLE OF CONTENTS INFO

View Full Filing

View this DEF 14A filing on SEC EDGAR